(NYSE American: VNRX) Focuses On Advancing The Science Of Epigenetics (5 Key Potential Catalysts)

A quiet force in the epigenetics sector is gaining attention

Any content you receive is for information purposes only. Always conduct your own research. *Sponsored (NYSE American: VNRX) Focuses On Advancing The Science Of Epigenetics (5 Key Potential Catalysts) *Click Here To Get Our Alerts Faster Via SMS* January 19th Dear Reader, A quiet force in the epigenetics sector is gaining attention for reshaping how disease detection can be approached. Drawing from cutting-edge molecular science, this company has been developing diagnostic technologies that could transform how clinicians identify and monitor critical health conditions. While its work remains under-the-radar compared to larger industry names, the potential real-world impact of its research is striking. With new studies underway and a growing presence across multiple regulatory markets, its momentum suggests it may soon become a key name in the conversation about accessible, noninvasive disease testing. And with an analyst target pointing to potential triple-digit upside, this little-known NYSE American profile is topping our watchlist Tuesday: VolitionRx Limited (NYSE American: VNRX) Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. And based on multiple potential catalysts, (NYSE American: VNRX) has taken over the top spot on our watchlist. Check them out: #1. A Significant Analyst Target ($2.50) May Signal Triple-Digit Potential Upside. #2. A Major Breakthrough Announced In Nu.Q® Vet Cancer Test Clinical Data. #3. The Company Just Solved A "Needle In A Haystack" Problem With 180-Fold (18,000%) Enrichment. #4. Volition Presents Two Abstracts At The NACLC (Now On the Path To The First Use Of Nu.Q® In Clinical Practice. #5. The First Sale Of Nu.Q® Cancer Assays Acts As A Major Milestone. But more on those in a second... Complete Company Overview - VolitionRx Limited Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help diagnose and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early diagnosis and monitoring have the potential not only to prolong the life of patients, but also improve their quality of life. Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and additional offices in London and Singapore. Early Diagnosis Saves Lives Imagine a world where diseases like cancer and sepsis can be diagnosed early and monitored easily using routine blood tests. That’s the world Volition is trying to build by developing their innovative family of simple, easy to use, cost-effective tests. Their patented technologies use chromosomal structures such as nucleosomes and transcription factors as biomarkers in cancer and other diseases. All the tests in their portfolio detect various characteristic changes that occur from the earliest stages of disease, enabling early detection and potentially a better way to monitor disease progression and a patient’s response to treatment. Nu.Q® Technology. The Company's ground breaking nucleosome quantification technology is currently being used for cancer applications in veterinary medicine and they are continuing to expand their technology in human medicine through early clinical trials in cancer, sepsis and beyond. Commercialization Strategy Underlying principles: low capex, low opex business model focused on commercial partnerships and outlicensing R&D -- R&D conducted by Volition and its research partners -- Monetize IP through licensing agreements with: upfront payments, milestone payments, recurring revenue from sales of key components & royalties Licensing and partnering criteria: -- Broad geographic reach -- Large installed base -- Experience of tech transfer -- Regulatory and clinical affairs -- Large sales and marketing teams 2026: Targeting multiple licensing deals in the human space Pioneering Liquid Biopsy Solving the "Needle in a Haystack" Problem One of the primary hurdles in liquid biopsy is the difficulty of detecting rare circulating tumor DNA (ctDNA) amidst a sea of healthy DNA. In December 2025, VNRX announced a technological breakthrough involving its Nu.Q® Capture technology. The company achieved a 180-fold (18,000%) enrichment of tumor-derived DNA. This advancement significantly enhances the sensitivity of sequencing, potentially allowing for the detection of cancer at much earlier stages when treatment is most effective. Strategic Expansion into Acute Care Beyond chronic disease, VNRX is targeting the high-stakes environment of intensive care units. The company's Nu.Q® NETs assay has been included in a major real-world evaluation in France for the early detection of sepsis. Sepsis is a leading cause of hospital mortality, and the ability to quantify Neutrophil Extracellular Traps (NETs) could provide doctors with a critical tool to identify at-risk patients hours or even days earlier than current methods. Robust Intellectual Property and Pipeline The company’s growth is underpinned by an extensive patent portfolio covering its nucleosome detection methods. Financial and Operational Strength As of the third quarter 2025, VNRX reported a cash position of approx. $12.3Mn. The company has been disciplined in its capital allocation, focusing on high-value commercial partnerships and streamlining its manufacturing processes. The management team, led by CEO Cameron Reynolds, brings decades of experience in the biotechnology sector, specifically in bringing novel diagnostic tools to global markets. Grab Sources And More Here: VNRX Website. VNRX Presentation. ----- And as I mentioned earlier, (NYSE American: VNRX) has several potential catalysts of focus. Take a look: #1. VNRX Potential Catalyst - A Significant Analyst Target ($2.50) May Signal Triple-Digit Potential Upside. Recently, Zacks Small-Cap Research analyst, Steven Ralston, provided coverage on (NYSE American: VNRX) with a price target of $2.50. From Friday's closing valuation, this target suggests a potential upside of 750+%. Here's some report highlights: Outlook: Management’s primary operational goal for 2025 is (was) to secure multiple licensing agreements for human diagnostic applications. In September Volition entered into two such licensing agreements. The company’s 1st commercial order for Nu.Q Cancer assays was received in November. The key financial goal for 2025 is (was) to achieve cash neutrality on a full-year basis. In 3Q 2025, cash burn was reduced to 1.2Mn per month. Papers, posters, conference presentations, webinars etc. continue on a brisk pace. ----- #2. VNRX Potential Catalyst - A Major Breakthrough Announced In Nu.Q® Vet Cancer Test Clinical Data. VolitionRx Announces Breakthrough Clinical Data for Nu.Q® Vet Cancer Test in Cats Paves the Way for World's First Feline Liquid Biopsy Test for Cancer Detection HENDERSON, Nev., Jan. 8, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces results from a clinical study demonstrating the high accuracy of its Nu.Q® Vet Feline assay in detecting lymphoma in cats, the most common cancer in the species. At 100% specificity, i.e. no false positives, the assay detected over 80% of feline lymphomas. This breakthrough marks the development of what we expect to be the world's first simple, affordable blood-based liquid biopsy test for feline cancer, a significant unmet need in veterinary medicine. Frédéric Wuilque, VP-Global Products, Volition commented: "Historically, cancer in cats has been notoriously difficult to diagnose early, often requiring invasive biopsies or expensive imaging after symptoms have already progressed. Veterinarians have been asking for a feline solution for years. Our mission is to make cancer screening a routine part of every pet's annual wellness check and following the successful international rollout of our canine cancer test, we have now demonstrated that our technology is also effective for cats. We look forward to completing product development and making the Nu.Q® Vet Feline Test available through our existing distribution networks including reference laboratories and point-of-care platforms." ... Read the full article here. ----- #3. VNRX Potential Catalyst - The Company Just Solved A "Needle In A Haystack" Problem With 180-Fold (18,000%) Enrichment. Volition Solves Liquid Biopsy's "Needle in a Haystack" Problem; Achieves 180-fold (18,000%) Enrichment HENDERSON, Nev., Dec. 11, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces preprint availability of a new manuscript entitled "Direct analysis of transcription factor protected cfDNA in plasma by ChIP-seq: Measurement of altered CTCF binding in cancer is a novel biomarker for liquid biopsy." This paper showcases both a new method, Capture-Seq™, and new biomarkers for the detection of cancer, holding the promise of accurate, low-cost tests for a wide range of cancers. Physical enrichment of ultrashort DNA fragments bound to a transcription factor is a key breakthrough allowing for the quantification in blood of combinations of potentially hundreds of binding sites associated with cancer that represent a new class of ultrashort DNA biomarkers not available to previous DNA analysis methods. Volition has achieved 180-fold enrichment (18,000%) through our unique focus on chromosome fragments – the form in which DNA actually exists in the blood. In contrast, current methods focus on the DNA itself after it has been chemically extracted from the blood, when its context within a chromosome has been lost. Dr Jake Micallef, Chief Scientific Officer, Volition commented: "This is, I believe, a world-first breakthrough – it is the first time that transcription factor-bound DNA has been physically separated from the massive amounts of background DNA in the blood, and could, in my opinion, represent the biggest scientific breakthrough in cancer testing in recent years. There is excitement in the world of liquid biopsy cancer DNA testing around the recent discoveries of ultrashort DNA fragments in the blood (including transcription factor-bound DNA), which hold great promise not only for accurate low-cost early cancer detection and cancer management, but also potentially for identifying the type of cancer present. Previous DNA liquid biopsy tests involve extraction of all DNA in the blood. A challenge faced by current technologies is that the overwhelming majority of DNA extracted from the blood is not cancer related but in fact "background" DNA. This background DNA interferes in DNA based liquid biopsy tests, especially tests for early-stage cancer. However, by isolating ultrashort DNA fragments bound to transcription factors using an antibody, Volition's technology removes 99% of background DNA before DNA extraction. Only ultrashort transcription factor-bound DNA is extracted and sequenced and the background DNA is washed away, solving the classic needle in a haystack problem. Moreover, this ultrashort transcription factor-bound DNA holds a great deal of additional information not available in the remaining 99% of DNA." ... Read the full article here. ----- #4. VNRX Potential Catalyst - Volition Presents Two Abstracts At The NACLC (Now On the Path To The First Use Of Nu.Q® In Clinical Practice. Volition Announces Two Abstracts were Presented at the North America Conference on Lung Cancer HENDERSON, Nev.,, December 8, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the presentation of two abstracts at the North America Conference on Lung Cancer (NACLC) in Chicago recently. The posters highlighted the use of its Nu.Q® Cancer assays in the management of lung cancer patients. ... Dr Andrew Retter, Chief Medical Officer of Volition, said: "Nu.Q® Cancer represents a significant advancement in lung cancer patient management, offering clinicians an additional tool to enhance precision in treatment selection and monitoring. Research conducted by our long-term collaborators in Lyon and Taiwan consistently demonstrates that our Nu.Q® Cancer technology empowers clinicians to make more informed treatment decisions and provides valuable new monitoring capabilities throughout the patient journey. By enriching clinical prognostication, Nu.Q® Cancer helps identify the most appropriate treatment pathway for an individual patient, supporting efforts to improve overall survival and deliver patient-centred care. We are now on the path to the first use of Nu.Q® in clinical practice, an exciting prospect which is core to Volition's mission, using our tests to help save lives." Read the full article here. ----- #5. VNRX Potential Catalyst - The First Sale Of Nu.Q® Cancer Assays Acts As A Major Milestone. VolitionRx Limited Announces the First Sale of the Nu.Q® Cancer Assays for Clinical Certification in Preparation for Routine Clinical Use HENDERSON, Nev., Nov. 25, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the first sale of its Nu.Q® Cancer assays to one of Europe's leading cancer centers, the Hospices Civils de Lyon, in Lyon, France. ... Dr. Andrew Retter, Chief Medical Officer, Volition, added: "Research conducted by the team at Lyon demonstrates that Nu.Q® Cancer technology empowers clinicians to make more informed treatment decisions and provides valuable new monitoring capabilities throughout the patient journey. By enriching clinical prognostication, Nu.Q® Cancer helps identify the most appropriate treatment pathway for an individual patient, supporting efforts to improve overall survival and deliver patient-centred care. Nu.Q® Cancer represents a significant advancement in lung cancer patient management, offering clinicians an additional tool to enhance precision in treatment selection and monitoring." Mr. Gael Forterre, Chief Commercial Officer, Volition concluded: "This is a major milestone for Volition in the commercialization and licensing of Nu.Q® in the human cancer field. We are now on the path to the first use of Nu.Q® in clinical practice, an exciting prospect which is core to Volition's mission, using our tests to help save lives. We look forward to providing more details soon." ... Read the full article here. ----- (NYSE American: VNRX) Recap - 5 Potential Catalysts On Watch #1. A Significant Analyst Target ($2.50) May Signal Triple-Digit Potential Upside. #2. A Major Breakthrough Announced In Nu.Q® Vet Cancer Test Clinical Data. #3. The Company Just Solved A "Needle In A Haystack" Problem With 180-Fold (18,000%) Enrichment. #4. Volition Presents Two Abstracts At The NACLC (Now On the Path To The First Use Of Nu.Q® In Clinical Practice. #5. The First Sale Of Nu.Q® Cancer Assays Acts As A Major Milestone. ----- Coverage is now officially underway on VolitionRx Limited (NYSE American: VNRX). Be on the lookout for updates coming your way shortly. Talk soon. Sincerely, FierceAnalyst | Jaks Swift Editorial Writer (Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.) *FierceInvestor (FierceInvestor . com) is owned by SWN Media LLC, a limited liability company. Data is provided from third-party sources and FierceInvestor ("FI") is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. We do not provide personalized fin-ancial advice, are not finan-cial advisors, and our opinions are not suitable for all in-vest-ors. Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 01/19/2026 and ending on 01/20/2026 to publicly disseminate information about (VNRX:US) via digital communications. Under this agreement, SWN Media LLC has been paid twenty thousand USD ("Funds"). These Funds were part of the funds that TD Media LLC received from a third party who did receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither SWN Media LLC, TD Media LLC and their member own shares of (VNRX:US). Please see important disclosure information here: https://fierceinvestor.com/disclosure/vnrx-g6zpb/#details

Fierce Investor | 4834 NW 2nd Ave Unit #388 | Boca Raton, FL 33431 US Unsubscribe | Update Profile | Constant Contact Data Notice